GO
Loading...

Enter multiple symbols separated by commas

Search results for "ABT"

REFINE RESULTS

SEARCH RESULTS

About 32 results. Sort By: Date | Relevance
Trades to wrap up a volatile week

The "Halftime Report" traders give their trades for the second half of the day.
Source: CNBC.com | By: Stephanie Landsman
4 Internet stocks to buy on earnings moves

"Fast Money" traders discussed how to play LinkedIn's battering and FireEye's pop in post-earnings trading.
Source: CNBC.com | By: Jacob Pramuk
Your first trade for Friday

The "Fast Money" traders give their final trades of the day.
Source: CNBC.com | By: Stephanie Landsman
Trades to go as April winds down

The "Halftime Report" traders give their trades for the second half.
Source: CNBC.com | By: Stephanie Landsman
Four trades to go before the closing bell

The "Halftime Report" traders give their top trades for the second half of the trading day.
Source: CNBC.com | By: Bree Kelly
Four trades to go before the closing bell

The "Halftime Report" traders give their top trades for the second half of the trading day.
Source: CNBC.com | By: Bree Kelly
Four trades to go as big earnings loom

The "Halftime Report" traders give their trades for the second half.
Source: CNBC.com | By: Stephanie Landsman
Abbott posts profit beat  

CNBC's Meg Tirrell reports on Abbott Laboratories' earnings and deals associated with this company.
Source: CNBC.com
UPDATE 1-Teva ready to divest operations to win regulatory nod for Mylan buy

April 22- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV. Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday.
Source: Reuters
UPDATE 1-Abbott profit beats expectations, sales of branded generics jump

April 22- Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions. The company's net earnings from continuing operations jumped to $529 million, or 35 cents per share, in the quarter ended March 31, from $224 million, or 14 cents per share, a year earlier.
Source: Reuters